Get the Stockscreener App
43.58
0.57%
-0.25
Exelixis Inc stock is traded at $43.58, with a volume of 2.49M.
It is down -0.57% in the last 24 hours and up +0.32% over the past month.
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.
See More
Previous Close:
$43.83
Open:
$43.52
24h Volume:
2.49M
Relative Volume:
0.92
Market Cap:
$11.68B
Revenue:
$2.17B
Net Income/Loss:
$521.27M
P/E Ratio:
24.62
EPS:
1.77
Net Cash Flow:
$633.79M
1W Performance:
-5.75%
1M Performance:
+0.32%
6M Performance:
-1.63%
1Y Performance:
+28.40%
1-Day Range:
$43.00
$43.73
1-Week Range:
$43.00
$46.29
52-Week Range:
$31.90
$49.62
Exelixis Inc Stock (EXEL) Company Profile
Name
Exelixis Inc
Sector
Industry
Phone
(650) 837-7000
Address
1851 HARBOR BAY PARKWAY, ALAMEDA, CA
Compare EXEL with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
EXEL
Exelixis Inc
|
43.58 | 11.75B | 2.17B | 521.27M | 633.79M | 1.77 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.13 | 115.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
776.31 | 81.12B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.17 | 52.54B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
839.99 | 51.78B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.12 | 37.12B | 447.02M | -1.18B | -906.14M | -6.1812 |
Exelixis Inc Stock (EXEL) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Peer Perform |
| Nov-03-25 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-21-25 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Sep-19-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Resumed | Barclays | Equal Weight |
| Sep-17-25 | Initiated | Goldman | Buy |
| Jul-08-25 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jun-24-25 | Upgrade | Stephens | Equal-Weight → Overweight |
| Feb-24-25 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Jan-27-25 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Jan-24-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Dec-20-24 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| Dec-17-24 | Downgrade | BofA Securities | Buy → Neutral |
| Oct-16-24 | Reiterated | RBC Capital Mkts | Outperform |
| Sep-19-24 | Initiated | UBS | Neutral |
| Apr-11-24 | Downgrade | Barclays | Overweight → Equal Weight |
| Dec-19-23 | Initiated | BTIG Research | Buy |
| Dec-15-23 | Initiated | Citigroup | Buy |
| Sep-26-23 | Initiated | H.C. Wainwright | Buy |
| Aug-22-23 | Reiterated | Oppenheimer | Outperform |
| Aug-08-23 | Initiated | SVB Securities | Market Perform |
| Jul-11-23 | Resumed | Morgan Stanley | Equal-Weight |
| May-10-23 | Resumed | Piper Sandler | Overweight |
| Mar-09-23 | Initiated | Wells Fargo | Overweight |
| Jan-26-23 | Initiated | Credit Suisse | Outperform |
| Oct-18-22 | Initiated | JMP Securities | Mkt Outperform |
| Jun-24-22 | Initiated | BMO Capital Markets | Outperform |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Nov-03-21 | Resumed | Jefferies | Buy |
| Oct-07-21 | Initiated | Jefferies | Buy |
| Aug-06-21 | Reiterated | H.C. Wainwright | Buy |
| Jun-15-21 | Initiated | H.C. Wainwright | Buy |
| May-18-21 | Resumed | Goldman | Sell |
| Mar-31-21 | Initiated | Credit Suisse | Outperform |
| Mar-12-21 | Initiated | Wolfe Research | Outperform |
| Mar-04-20 | Initiated | Barclays | Overweight |
| Jan-13-20 | Initiated | SunTrust | Buy |
| Nov-13-19 | Initiated | BofA/Merrill | Buy |
| Mar-18-19 | Upgrade | Morgan Stanley | Underweight → Equal-Weight |
| Sep-17-18 | Initiated | Goldman | Neutral |
| Sep-10-18 | Initiated | Morgan Stanley | Underweight |
| May-11-18 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | Needham | Buy |
| Oct-17-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-16-17 | Reiterated | SunTrust | Buy |
| Sep-22-17 | Downgrade | Leerink Partners | Outperform → Mkt Perform |
| Sep-15-17 | Initiated | RBC Capital Mkts | Outperform |
| Sep-12-17 | Reiterated | Needham | Buy |
| Jul-14-17 | Initiated | SunTrust | Buy |
| Mar-31-17 | Initiated | Needham | Buy |
| Mar-16-17 | Initiated | Oppenheimer | Perform |
| Feb-28-17 | Downgrade | Stifel | Buy → Hold |
| Nov-03-16 | Initiated | Deutsche Bank | Buy |
| Oct-10-16 | Upgrade | Piper Jaffray | Neutral → Overweight |
| Sep-15-16 | Reiterated | Stifel | Buy |
View All
Exelixis Inc Stock (EXEL) Latest News
Aug Sectors: Is Exelixis Inc EX9 stock cheap vs fundamentalsEarnings Trend Report & Free Fast Entry Momentum Trade Alerts - moha.gov.vn
Exelixis Announces Key Senior Leadership Hires in Medical Affairs, Sales, & Marketing to Support Commercialization of Cabozan... - ADVFN
See How Rare Bullish Inflows Lift Outliers Like Exelixis - Yahoo Finance
Here's Why Exelixis (EXEL) is a Strong Growth Stock - Yahoo Finance
Trading the Move, Not the Narrative: (EXEL) Edition - Stock Traders Daily
EXELExelixis Announces Second Quarter 2013 Financial Results - ADVFN
Does Exelixis (NASDAQ:EXEL) Deserve A Spot On Your Watchlist? - Yahoo Finance
Exelixis Reports Positive Preliminary Phase 2 Cabozantinib Data in Patients with Hepatocellular Carcinoma - ADVFN
Exelixis Announces Initiation of Investigator-Sponsored Clinical Trial Combining Cabozantinib & Abiraterone in Men With Castr... - ADVFN
Exelixis Announces Positive Overall Survival Results from Phase 3 Pivotal Trial of Cobimetinib in Combination with Vemurafeni... - ADVFN
Exelixis Inc Stock Analysis and ForecastLarge Cap Stability Picks & Double Or Triple Capital - earlytimes.in
Exelixis Announces Presentation of Updated Phase 1b Results for the Combination of Cobimetinib & Atezolizumab in Metastatic C... - ADVFN
Exelixis Announces Results from a Phase 2 Investigator-Sponsored Trial of Cabozantinib in the First-Line Treatment of Metasta... - ADVFN
Exelixis Receives $150 Million Funding Commitment From Deerfield Management - ADVFN
Exelixis Expands the Cabozantinib Development Program Through NCI-CTEP Collaboration - ADVFN
Exelixis Announces Phase 1 Trial Results for Cabozantinib in Combination with Nivolumab with or without Ipilimumab in Refract... - ADVFN
Exelixis Earnings Notes - Trefis
History Review: Is Exelixis Inc stock trading at a premium valuationPortfolio Return Summary & Free Expert Approved Momentum Trade Ideas - moha.gov.vn
Exelixis (MIC:EXEL-RM) EV-to-FCF : 0.00 (As of Dec. 26, 2025) - GuruFocus
Exelixis (HAM:EX9) EV-to-OCF : 13.21 (As of Dec. 22, 2025) - GuruFocus
Why Exelixis, Inc. (EXEL) Skyrocketed On Wednesday - MSN
Published on: 2025-12-21 13:28:36 - Улправда
How Exelixis Inc. stock reacts to job market dataMarket Risk Report & Safe Swing Trade Setups - ulpravda.ru
Behavioral Patterns of EXEL and Institutional Flows - news.stocktradersdaily.com
Published on: 2025-12-20 10:46:18 - Улправда
Can Exelixis Inc. stock hit analyst price targetsJuly 2025 Levels & Growth Focused Stock Reports - Улправда
Exelixis and Merck Advance LITESPARK-033: A New Kidney Cancer Combo With High-Stakes Market Potential - TipRanks
Exelixis (FRA:EX9) EV-to-OCF : 12.63 (As of Dec. 19, 2025) - GuruFocus
Will Exelixis Inc. stock benefit from infrastructure spendingJuly 2025 Sector Moves & AI Based Trade Execution Alerts - DonanımHaber
Gap Down: Can Exelixis Inc. (EX9) stock stage a strong rebound this quarterPortfolio Value Report & Short-Term Swing Trade Alerts - DonanımHaber
Is Exelixis Inc. stock a defensive play in 2025July 2025 Levels & Real-Time Market Trend Scan - DonanımHaber
Rally Mode: How analysts revise price targets for Exelixis Inc. (EX9) stock2025 Biggest Moves & Precise Buy Zone Tips - Улправда
Stelios Papadopoulos brings the long view on biotech on The BioCentury Show - biocentury.com
Returns Recap: How Exelixis Inc EX9 stock compares with top peersQuarterly Profit Report & Real-Time Buy Zone Alerts - moha.gov.vn
Why Exelixis Inc. (EX9) stock stays on buy listsWeekly Profit Analysis & Verified Stock Trade Ideas - ulpravda.ru
Why Exelixis (EXEL) is a Top Value Stock for the Long-Term - Yahoo Finance
Citizens reiterates Market Outperform rating on Exelixis stock at $50 By Investing.com - Investing.com Canada
Exelixis, Inc.Common Stock (NQ: EXEL - FinancialContent
Why Exelixis (EXEL) is a Top Growth Stock for the Long-Term - Yahoo Finance
Analysts Are Bullish on Top Healthcare Stocks: Owlet (OWLT), Exelixis (EXEL) - The Globe and Mail
VP Haley Files To Sell 23,539 Of Exelixis Inc [EXEL] - TradingView — Track All Markets
Exelixis Inc (HAM:EX9)Valuation Measures & Financial Statistics - GuruFocus
Analysts Offer Insights on Healthcare Companies: Hinge Health, Inc. Class A (HNGE), Exelixis (EXEL) and Natera (NTRA) - theglobeandmail.com
Exelixis Inc (HAM:EX9) Dividend - GuruFocus
GI Cancer Immunotherapy Breakthroughs Signal New Treatment Era - The Manila Times
Exelixis (EXEL) Receives a Hold from RBC Capital - theglobeandmail.com
Exelixis stock holds steady as Stifel maintains $43 price target By Investing.com - Investing.com Canada
Exelixis, Inc. (EXEL) Discusses Strategic Approach to Building Next-Generation Oncology Franchises at R&D DaySlideshow (NASDAQ:EXEL) 2025-12-11 - Seeking Alpha
EXEL to Host Research and Development Day in December - GuruFocus
Analyst Upgrade: Can Exelixis Inc EX9 stock stage a strong rebound this quarterSell Signal & Daily Profit Focused Stock Screening - moha.gov.vn
(EXEL) Movement Within Algorithmic Entry Frameworks - news.stocktradersdaily.com
Exelixis Inc Stock (EXEL) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.57%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):